KRAS G12S MUTATIONS

Clinical trials for KRAS G12S MUTATIONS explained in plain language.

Never miss a new study

Get alerted when new KRAS G12S MUTATIONS trials appear

Sign up with your email to follow new studies for KRAS G12S MUTATIONS, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.

Our safety recommendation!

By submitting, you agree to our Terms of use

Not yet recruiting 1

New pill targets Hard-to-Treat cancers with KRAS mutations

Disease control Not yet recruiting

This early-phase study tests a new daily pill, KQB368, in adults with advanced solid tumors (like lung, colon, or uterine cancer) that have a KRAS G12S or G12C mutation and no standard cure. The main goals are to find a safe dose and see if the drug can shrink tumors. About 48 pa…

Matched conditions: KRAS G12S MUTATIONS

Phase: PHASE1 • Sponsor: Kumquat Biosciences Inc. • Aim: Disease control

Last updated Apr 29, 2026 15:04 UTC

KRAS G12S MUTATIONS

Get alerted when new KRAS G12S MUTATIONS trials appear

New pill targets Hard-to-Treat cancers with KRAS mutations